EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study

Hiroshi Okuda, Manabu Shimomura, Satoshi Ikeda, Masahiro Nakahara, Masashi Miguchi, Yasuyo Ishizaki, Yasuhumi Saitoh, Kazuhiro Toyota, Daisuke Sumitani, Yosuke Shimizu, Yuji Takakura, Wataru Shimizu und 7 weitere

Cancer Chemotherapy and Pharmacology · 2023

DOI: 10.1007/s00280-023-04526-7 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Hiroshi Okuda und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tegafur. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: There is no consensus on the safety and effectiveness of adjuvant chemotherapy for patients with stage III colorectal cancer (CRC) aged ≥ 80 years. We conducted a prospective multi-institutional phase II study of uracil-tegafur and leucovorin (UFT/LV) as adjuvant chemotherapy in this population. PATIENTS AND METHODS: Patients with stage III CRC aged ≥ 80 years who underwent curative resection were enrolled. Eligible patients received UFT/LV therapy (UFT, 300 mg/m2 per day as tegafur; LV, 75 mg/day on days 1-28, every 35 days for five courses). Primary endpoint was feasibility, and secondary endpoints were safety and relative dose intensity. RESULTS: Sixty-nine patients were enrolled between 2013 and 2021. Of the 69 patients, 65 were included in the analysis. There were 32 males and 33 females with a median age of 82 years (range 80-88 years). In the primary endpoint, administration completion rate was 67.3% (95% confidence interval 54.9-77.6%), and the lower limit of the 95% confidence interval was below the threshold of 60%. 21 patients discontinued treatment because of adverse events (AEs) and refused treatment. The median relative dose intensities were 84% (range 4-100%) for UFT, and 100% (range 4-100%) for LV. Incidence of grade three or higher AEs were neutropenia (1.5%), aspartate transaminase elevation (3%), alanine transaminase elevation (1.5%), oral mucositis (3%), anemia (1.5%), and diarrhea (4.6%). CONCLUSIONS: The indications for adjuvant UFT/LV therapy for elderly CRC aged ≥ 80 years were considered limited. It is necessary to clarify the background of patients in whom drug administration is discontinued and investigate their impact on long-term prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTegafurAgedAged, 80 and overFemaleHumansMaleAdministration, OralAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFeasibility StudiesLeucovorinProspective StudiesUracil

Stichwörter der Autor:innen

Adjuvant chemotherapyColorectal cancerElderlyUracil–tegafur and leucovorin

Substanzen

LeucovorinTegafurUracil

Autor:innen und Institutionen

  • Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Surgery, Onomichi General Hospital, Onomichi, Japan.
  • Department of Surgery, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
  • Department of Surgery, Hiroshima Prefectural Hospital, 1-5-54, Ujina-Kanda, Minami-ku, Hiroshima, Japan. sikeda1965@gmail.com.
  • Department of Surgery, Hiroshima Prefectural Hospital, 1-5-54, Ujina-Kanda, Minami-ku, Hiroshima, Japan.
  • Department of Surgery, National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan.

Zitieren

APA

Okuda, H., Shimomura, M., Ikeda, S., Nakahara, M., Miguchi, M., Ishizaki, Y., Saitoh, Y., Toyota, K., Sumitani, D., Shimizu, Y., Takakura, Y., Shimizu, W., Yoshimitsu, M., Kodama, S., Fujimori, M., Oheda, M., Kobayashi, H., Ohdan, H., & Hiroshima Surgical Study Group of Clinical Oncology (HiSCO) (2023). A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04526-7

Vancouver

Okuda H, Shimomura M, Ikeda S, Nakahara M, Miguchi M, Ishizaki Y, et al. A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04526-7

BibTeX
@article{Okuda2023,
  author = {Okuda, Hiroshi and Shimomura, Manabu and Ikeda, Satoshi and Nakahara, Masahiro and Miguchi, Masashi and Ishizaki, Yasuyo and Saitoh, Yasuhumi and Toyota, Kazuhiro and Sumitani, Daisuke and Shimizu, Yosuke and Takakura, Yuji and Shimizu, Wataru and Yoshimitsu, Masanori and Kodama, Shinya and Fujimori, Masahiko and Oheda, Mamoru and Kobayashi, Hironori and Ohdan, Hideki and Hiroshima Surgical Study Group of Clinical Oncology (HiSCO), Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)},
  title = {A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2023},
  doi = {10.1007/s00280-023-04526-7}
}
Kostenlos starten →